Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people.

Hall RG 2nd, Swancutt MA, Meek C, Leff RD, Gumbo T.

Antimicrob Agents Chemother. 2012 Mar;56(3):1502-7. doi: 10.1128/AAC.05623-11.

2.

Evolving Larger: Dosing Anti-Tuberculosis (TB) Drugs in an Obese World.

Hall RG 2nd.

Curr Pharm Des. 2015;21(32):4748-51. Review.

PMID:
26112269
3.

Ethambutol dosage for the treatment of children: literature review and recommendations.

Donald PR, Maher D, Maritz JS, Qazi S.

Int J Tuberc Lung Dis. 2006 Dec;10(12):1318-30. Review.

PMID:
17167947
4.

Pediatric Obesity: Pharmacokinetics and Implications for Drug Dosing.

Kendrick JG, Carr RR, Ensom MH.

Clin Ther. 2015 Sep 1;37(9):1897-923. doi: 10.1016/j.clinthera.2015.05.495. Review.

PMID:
26361823
5.

Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review.

Davies-Vorbrodt S, Ito JI, Tegtmeier BR, Dadwal SS, Kriengkauykiat J.

Pharmacotherapy. 2013 Jan;33(1):22-30. doi: 10.1002/phar.1156. Review.

PMID:
23307541
6.

Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology.

Martin JH, Saleem M, Looke D.

Br J Clin Pharmacol. 2012 May;73(5):685-90. doi: 10.1111/j.1365-2125.2011.04159.x. Review.

Supplemental Content

Support Center